Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Capital Leases: 2020-2025

Historic Capital Leases for Rocket Pharmaceuticals (RCKT) over the last 6 years, with Sep 2025 value amounting to $19.4 million.

  • Rocket Pharmaceuticals' Capital Leases fell 0.04% to $19.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.4 million, marking a year-over-year decrease of 0.04%. This contributed to the annual value of $19.4 million for FY2024, which is 0.16% up from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Capital Leases stood at $19.4 million, which was down 0.03% from $19.4 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Capital Leases ranged from a high of $19.4 million in Q4 2024 and a low of $19.0 million during Q1 2021.
  • For the 3-year period, Rocket Pharmaceuticals' Capital Leases averaged around $19.4 million, with its median value being $19.4 million (2024).
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Capital Leases rose by 0.93% in 2021, and later dropped by 0.04% in 2025.
  • Rocket Pharmaceuticals' Capital Leases (Quarterly) stood at $19.1 million in 2021, then climbed by 0.65% to $19.3 million in 2022, then rose by 0.44% to $19.4 million in 2023, then climbed by 0.16% to $19.4 million in 2024, then declined by 0.04% to $19.4 million in 2025.
  • Its Capital Leases stands at $19.4 million for Q3 2025, versus $19.4 million for Q2 2025 and $19.4 million for Q1 2025.